Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 8701128 Publication Model: Print Cited Medium: Internet ISSN: 1525-6049 (Electronic) Linking ISSN: 0886022X NLM ISO Abbreviation: Ren Fail Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: New York, N.Y. : M. Dekker, c1987-

Lupus Nephritis/*blood ; Lupus Nephritis/*urine ; Tumor Necrosis Factors/*blood ; Tumor Necrosis Factors/*urine; Biomarkers/blood ; Biomarkers/urine ; Cytokine TWEAK ; Humans ; Lupus Erythematosus, Systemic/complications

Purpose: Accumulative studies showed that tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) was up-regulated in the blood and urine from patients diagnosed with lupus nephritis (LN) and that it might be used as a novel biomarker for active LN. This meta-analysis aimed to determine the diagnostic value of TWEAK in active LN.
Methods: We searched the Cochrane Library, Embase, PubMed, Springer, Wanfang and CNKI databases for articles published up to 20 August 2020. The diagnostic capacity of TWEAK for active LN was assessed using pooled sensitivity and specificity, positive and negative likelihood ratios (PLR and NLR), diagnostic odds ratio (DOR), and area under the receiver operating characteristic curve (AUC). Quality assessment and publication bias were also evaluated. STATA 11.0 and Meta-Disc 1.4 were used to perform these analyses.
Results: Nine cross-sectional studies were included in this meta-analysis. The overall pooled sensitivity of TWEAK for the diagnosis of active LN was 0.69 (95% CI, 0.63-0.75), and specificity was 0.77 (95% CI, 0.71-0.82). The overall pooled PLR and NLR were 3.31 (95% CI, 2.05-5.35) and 0.38 (95% CI, 0.26-0.55), respectively, with a DOR of 10.89 (95% CI, 6.73-17.63) and AUC (SE) of 0.8276 (0.0289). Deeks' funnel plot revealed that the publication bias was insignificant in the study ( p  = .32).
Conclusions: Our results suggest that TWEAK might be a potential biomarker for patients with active LN. Future cross-sectional and longitudinal studies are needed to confirm its diagnostic value, as well as to establish more definite cutoff for active LN.

Korean J Intern Med. 2018 Mar;33(2):284-289. (PMID: 29320847)
Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i71-i79. (PMID: 28391335)
Arthritis Res Ther. 2018 Jan 11;20(1):6. (PMID: 29325582)
Inflamm Res. 2016 Jun;65(6):479-88. (PMID: 26921306)
Clin Exp Immunol. 2017 Apr;188(1):79-85. (PMID: 27936517)
Lupus. 2018 May;27(6):971-981. (PMID: 29451067)
Arthritis Res Ther. 2009;11(6):133. (PMID: 19951398)
Nat Commun. 2017 May 22;8:15395. (PMID: 28530223)
Clin Immunol. 2017 Dec;185:10-20. (PMID: 27498110)
Arthritis Care Res (Hoboken). 2015 Oct;67(10):1440-52. (PMID: 25778500)
Mol Biol Rep. 2011 Jan;38(1):587-92. (PMID: 20358293)
Medicine (Baltimore). 2018 Apr;97(16):e0343. (PMID: 29668584)
Clin J Am Soc Nephrol. 2017 May 8;12(5):825-835. (PMID: 27821390)
Arthritis Res Ther. 2017 Oct 24;19(1):242. (PMID: 29065913)
Z Rheumatol. 2018 Feb;77(1):71-77. (PMID: 27619369)
Clin Immunol. 2012 Nov;145(2):108-21. (PMID: 22982296)
Lupus. 2020 Apr;29(4):379-388. (PMID: 32041504)
Clin Chem. 2017 Sep;63(9):1515-1526. (PMID: 28667184)
Cell. 2005 Dec 2;123(5):931-44. (PMID: 16325585)
J Am Soc Nephrol. 2015 May;26(5):1053-70. (PMID: 25270074)
Nephrology (Carlton). 2011 May;16(4):426-32. (PMID: 21303425)
Cytokine. 2011 Mar;53(3):295-300. (PMID: 21163672)
Dtsch Arztebl Int. 2014 Sep 12;111(37):617-25; quiz 626. (PMID: 25283761)
Lupus Sci Med. 2019 Apr 9;6(1):e000298. (PMID: 31168397)
Ann Intern Med. 2011 Oct 18;155(8):529-36. (PMID: 22007046)
Tohoku J Exp Med. 2018;244(4):263-270. (PMID: 29576585)
J Immunol. 2007 Dec 1;179(11):7949-58. (PMID: 18025243)
Ren Fail. 2020 Nov;42(1):244-254. (PMID: 32228220)
Rheumatology (Oxford). 2007 Apr;46(4):649-52. (PMID: 17065189)
BMC Urol. 2019 Aug 6;19(1):76. (PMID: 31387648)
Arthritis Rheum. 2012 Aug;64(8):2677-86. (PMID: 22553077)
Ren Fail. 2020 Nov;42(1):19-29. (PMID: 31858861)
Cell Signal. 2020 Jul;71:109615. (PMID: 32217132)
Inflammation. 2012 Jun;35(3):935-43. (PMID: 22009442)
Kidney Int. 2018 Apr;93(4):789-796. (PMID: 29459092)
Arthritis Res Ther. 2009;11(5):R143. (PMID: 19785730)
Kidney Int. 2011 Oct;80(7):708-18. (PMID: 21697814)
Arthritis Rheum. 1997 Sep;40(9):1725. (PMID: 9324032)
Panminerva Med. 2016 Dec;58(4):286-293. (PMID: 27598890)
J Biomed Biotechnol. 2012;2012:359647. (PMID: 22719208)
Arthritis Rheum. 1982 Nov;25(11):1271-7. (PMID: 7138600)
Biomark Med. 2015;9(6):529-43. (PMID: 26079958)
Immunol Res. 2016 Feb;64(1):44-50. (PMID: 26659091)
Nefrologia. 2018 Mar - Apr;38(2):152-160. (PMID: 28755900)
Immunity. 2001 Nov;15(5):837-46. (PMID: 11728344)
Clin Rev Allergy Immunol. 2011 Jun;40(3):138-50. (PMID: 20127204)
Arthritis Rheumatol. 2014 Jan;66(1):130-9. (PMID: 24449580)
Arthritis Rheumatol. 2016 Jun;68(6):1432-41. (PMID: 26815601)
J Clin Immunol. 2011 Oct;31(5):848-56. (PMID: 21691937)
Immunol Rev. 2011 Nov;244(1):99-114. (PMID: 22017434)
J Biomed Biotechnol. 2010;2010:638413. (PMID: 20414362)

Keywords: TWEAK; diagnosis; lupus nephritis; meta-analysis

0 (Biomarkers)
0 (Cytokine TWEAK)
0 (TNFSF12 protein, human)
0 (Tumor Necrosis Factors)

Date Created: 20201214 Date Completed: 20210830 Latest Revision: 20210830

20240104

PMC7745842

10.1080/0886022X.2020.1853568

33307926